Related Experiment Video

Updated: May 26, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C

E Degasperi1, A Aghemo

  • 1AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

Journal of Viral Hepatitis
|January 12, 2012
PubMed

Insights

Hepatitis C virus (HCV) treatment can prevent liver disease progression and complications. Expanding therapy eligibility may reduce long-term liver-related deaths, despite potential side effects and inaccurate response predictions.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Hepatitis C virus (HCV) infection is a global health concern, leading to cirrhosis and liver transplantation.
  • Peginterferon and Ribavirin therapy is the sole option to prevent fibrosis progression and liver complications in chronic hepatitis C.
  • Serious side effects limit universal treatment, leading to eligibility criteria based on clinical factors.

Purpose of the Study:

  • To evaluate the benefits of expanding Hepatitis C virus (HCV) treatment eligibility beyond current guidelines.
  • To address the limitations of baseline predictions for sustained virological response (SVR).
  • To explore the long-term impact of increased treatment rates on liver-related mortality.

Main Methods:

  • Review of current international guidelines for HCV treatment eligibility.
  • Analysis of evidence regarding treatment benefits in patients with mild fibrosis.
  • Assessment of the role of on-therapy HCV kinetics in predicting treatment outcomes.
  • Evaluation of the long-term epidemiological impact of increased treatment rates.

Main Results:

  • Current guidelines recommend treatment based on liver disease severity, predicted SVR, and adverse event risk.
  • Evidence suggests treatment benefits patients with mild fibrosis, contrary to strict eligibility criteria.
  • Baseline predictions of SVR are often inaccurate due to the dynamic nature of HCV kinetics during treatment.
  • Increased patient treatment numbers are projected to reduce long-term liver-related deaths.

Conclusions:

  • HCV treatment is crucial for preventing liver disease progression and complications.
  • Current eligibility criteria may be too restrictive, potentially excluding patients who could benefit from therapy.
  • A broader treatment approach, considering on-therapy response, could improve patient outcomes and reduce mortality.
  • Expanding HCV treatment programs is a viable strategy for long-term public health benefit.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...